Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 5, 2006, Pages 516-527

  Wildeboer, Dirk ^a   Naus, Silvia ^a   Sang, Qing Xiang Amy ^c   Bartsch, Jörg W ^a,b   Pagenstecher, Axel ^d,e  

^a BIELEFELD UNIVERSITY   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c FLORIDA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

ADAMs; Brain neoplasms; Invasive gliomas; Matrix metalloproteinases

Indexed keywords

ADAM 10; ADAM 11; ADAM 12; ADAM 15; ADAM 19; ADAM 2; ADAM 22; ADAM 23; ADAM 28; ADAM 8; ADAM 9; DISINTEGRIN; METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; ADAM PROTEIN; ADAM19 PROTEIN, HUMAN; ADAM8 PROTEIN, HUMAN; MEMBRANE PROTEIN; MESSENGER RNA;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER INVASION; CELL INVASION; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME REGULATION; ENZYME SUBSTRATE; EPENDYMOMA; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN TISSUE; NEUROECTODERM TUMOR; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULAR TUMOR; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADAM PROTEINS; ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; METALLOPROTEASES; NEOPLASM INVASIVENESS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33745689524     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000229240.51490.d3     Document Type: Article

References (45)

1. Kleihues P, Cavanee WK eds. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000
2. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999;100:216-32
3. Mohanam S, Wang SW, Rayford A, et al. Expression of tissue inhibitors of metalloproteinases: Negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis 1995;13:57-62
4. Forsyth PA, Wong H, Laing TD, et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999;79:1828-35
5. Nakada M, Nakamura H, Ikeda E, et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999;154:417-28
6. Lampert K, Machein U, Machein MR, Conca W, Peter HH, Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 1998;153:429-37
7. Nakagawa T, Kubota T, Kabuto M, et al. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 1994;81:69-77
8. Beliveau R, Delbecchi L, Beaulieu E, et al. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Ann N Y Acad Sci 1999;886:236-39
9. Pagenstecher A, Wussler EM, Opdenakker G, Volk B, Campbell IL. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol 2001;60:598-612
10. Nuttall RK, Pennington CJ, Taplin J, et al. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res 2003;1:333-45
11. Belien AT, Paganetti PA, Schwab ME. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol 1999;144:373-84
12. Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000;97:3884-89
13. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest 1999;103:1237-41
14. Price A, Shi Q, Morris D, et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 1999;5:845-54
15. Bello L, Lucini V, Carrabba G, et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res 2001;61:8730-36
16. Lakka SS, Rajan M, Gondi C, et al. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 2002;21:8011-19
17. Tonn JC, Kerkau S, Hanke A, et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer 1999;80:764-72
18. Noha M, Yoshida D, Watanabe K, Teramoto A. Suppression of cell invasion on human malignant glioma cell lines by a novel matrix-metalloproteinase inhibitor SI-27: in vitro study. J Neurooncol 2000;48:217-23
19. Yoshida D, Watanabe K, Noha M, Takahashi H, Teramoto A, Sugisaki Y. Anti-invasive effect of an anti-matrix metalloproteinase agent in a murine brain slice model using the serial monitoring of green fluorescent protein-labeled glioma cells. Neurosurgery 2003;52:187-96. discussion 96-97
20. Bauvois B. Transmembrane proteases in cell growth and invasion: New contributors to angiogenesis? Oncogene 2004;23:317-29
21. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nature Rev Neurosci 2001;2:502-11
22. Duffy MJ, Lynn DJ, Lloyd AT, O'Shea CM. The ADAMs family of proteins: From basic studies to potential clinical applications. Thromb Haemost 2003;89:622-31
23. Kodama T, Ikeda E, Okada A, et al. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 2004;165:1743-53
24. Zhao YG, Wei P, Sang QX. Inhibitory antibodies against endopeptidase activity of human adamalysin 19. Biochem Biophys Res Commun 2001;289:288-94
25. Schlomann U, Wildeboer D, Webster A, et al. The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J Biol Chem 2002;277:48210-19
26. Kang T, Park HI, Suh Y, Zhao YG, Tschesche H, Sang QX. Autolytic processing at Glu586-Ser587 within the cysteine-rich domain of human adamalysin 19/disintegrin-metalloproteinase 19 is necessary for its proteolytic activity. J Biol Chem 2002;277:48514-22
27. Schlomann U, Rathke-Hartlieb S, Yamamoto S, Jockusch H, Bartsch JW. Tumor necrosis factor alpha induces a metalloprotease-disintegrin, ADAM8 (CD 156): Implications for neuron-glia interactions during neurodegeneration. J Neurosci 2000;20:7964-71
28. Naus S, Richter M, Wildeboer D, Moss M, Schachner M, Bartsch JW. Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem 2004;279:16083-90
29. Fourie AM, Coles F, Moreno V, et al. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23 MDC-L, a novel metalloprotease disintegrin cysteine-rich protein family member expressed by human lymphocytes. J Biol Chem 2003;278:30469-77
30. Naus S, Reipschlaeger S, Wildeboer D, Guggemooser, Bartsch JW. Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8. Biol Chem 2006;387:337-46
31. Amour A, Knight CG, English WR, et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett 2002;524:154-8
32. Choi SJ, Han JH, Roodman GD. ADAM8: A novel osteoclast stimulating factor. J Bone Miner Res 2001;16:814-22
33. King NE, Zimmermann N, Pope SM, Fulkerson PC, Nikolaidis NM, Mishra A, Witte DP, Rothenberg ME. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am J Respir Cell Mol Biol 2004;31:257-65
34. Kelly K, Hutchinson G, Nebenius-Oosthuizen D, et al. Metalloprotease- disintegrin ADAM8: Expression analysis and targeted deletion in mice. Dev Dyn 2005;232:221-31
35. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 2002;160:673-80
36. Kurohara K, Komatsu K, Kurisaki T, et al. Essential roles of Meltrin beta (ADAM19) in heart development. Dev Biol 2004;267:14-28
37. Zhou HM, Weskamp G, Chesneau V, et al. Essential role for ADAM19 in cardiovascular morphogenesis. Mol Cell Biol 2004;24:96-104
38. Shirakabe K, Wakatsuki S, Kurisaki T, Fujisawa-Sehara A. Roles of Meltrin beta/ADAM19 in the processing of neuregulin. J Biol Chem 2001;276:9352-58
39. Gollamudi M, Nethery D, Liu J, Kern JA. Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines. Lung Cancer 2004;43:135-43
40. Andersson U, Guo D, Malmer B, et al. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol (Berl) 2004;108:135-42
41. Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 2003;22:2411-21
42. Reddy P, Slack JL, Davis R, et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 2000;275:14608-14
43. Deryugina EI, Bourdon MA, Luo GX, Reisfeld RA, Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci 1997;110:2473-82
44. Bello L, Giussani C, Carrabba G, et al. Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. Clin Cancer Res 2002;8:3539-48
45. Ishikawa N, Daigo Y, Yasui W, et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004;10:8363-70